GRF (mL/min) · primary immunosuppression in kidney transplant recipients
1 finding from 1 review
Hypercholesterolaemia · primary immunosuppression in kidney transplant recipients
Low probably leads to lower hypercholesterolaemia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).
1 finding from 1 review
Anaemia · primary immunosuppression in kidney transplant recipients
Low may leads to lower anaemia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).
1 finding from 1 review
Thrombocytopenia · primary immunosuppression in kidney transplant recipients
Low may leads to lower thrombocytopenia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).
1 finding from 1 review
Intervention not reported
Change in endothelial function: Change in flow‐mediated dilatation of brachial artery (%) · children with familial hypercholesterolemia
1 finding from 1 review
Intervention not reported
Any depression Multiple measures used. CES‐D (Blanchard 1996;McCorkle 2007). POMS Depression subscale (Bultz 2000). HADS‐D (Nicolaisen 2018; Robertson 2016). Higher scores indicate higher levels of depression. Folllow‐up: Three to six months post‐... · informal caregivers of people affected by cancer
1 finding from 1 review
Sleep quality Assessed by average duration of slow‐wave and REM sleep periods · adults with obstructive sleep apnoea
1 finding from 1 review
Sleep quality Assessed by average duration of slow‐wave and REM sleep periods · adults with obstructive sleep apnoea
1 finding from 1 review
Intervention not reported
Intervention: high‐dose radiotherapy Comparison: low‐dose radiotherapy Outcome: neurocognitive impairment at 2 years after treatment · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: high‐dose radiotherapy Comparison: low‐dose… (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention: high‐dose radiotherapy Comparison: low‐dose radiotherapy Outcome: neurocognitive impairment at 5 years after treatment · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: high‐dose radiotherapy Comparison: low‐dose… (very low certainty).
1 finding from 1 review
Improvement in lower limb perfusion: ABI · people with critical limb ischaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in lower limb perfusion: TcO₂ reading in mmHg · people with critical limb ischaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Low‐fibre diet · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Low‐fat diet · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in pneumonia: low‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA probably leads to lower moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in pneumonia: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review